Free shipping on all products above £200
Get updates on research date daily now
Retatrutide
Pre-Filled Pen Evaluation
Part of Alluvi Labs’ ongoing research program into advanced GLP-1 multi-agonist compounds.
This formulation is supplied in controlled batches for laboratory analysis of stability, compound behaviour, and injector system performance.
Not for human or veterinary consumption. Alluvi HealthCare Website.
Best Selling Alluvi
Alluvi Supplement Box
£250.00
Alluvi
£250.00
Alluvi
£225.00
Alluvi
£200.00
Alluvi
£270.00
Alluvi
£200.00
Alluvi
£300.00
Alluvi
£210.00
£499.00
£1,349.00
Alluvi
£300.00
£1,349.00
£499.00
£499.00
£1,349.00
£1,349.00
Track. Dose. Progress.
The Alluvi app supports wellness goals with smart tracking, log nutrition, monitor weight, and stay consistent through a modern mobile dashboard.
No setup. No stress, only accurate dosing.
Alluvi pens come ready for immediate use – no preparation, no uncertainty.
Created specifically for controlled research environments, each device contains precisely measured doses to ensure consistency and dependability throughout testing. Not intended for human or animal use.
Monitor Results. Enhance Research.
From peptide pens to nutritional gummies, Alluvi’s solutions enable structured data collection, progress tracking, and weekly performance summaries – ensuring reliable insights within regulated research and development projects.
Not intended for human or animal use.
Proven Data. Backed by Research.
Published studies have investigated GLP-1 multi-agonist compounds under controlled conditions.
Alluvi supplies Retatrutide pens exclusively for laboratory research and development.
Not for human or veterinary consumption.
All figures are derived from third-party published studies and are shown only for academic context. All Alluvi products are supplied strictly for laboratory research purposes.
1.) 22.5%
loss in weight using Retatrutide
Reference value drawn from published research on GLP-1 multi-agonist compounds.
Provided strictly as scientific context.
2.) 6oo
Clinical Study based on 600 calorie reduction in daily intake
Participants consumed fewer calories per day without being instructed to diet – driven by decreased appetite and satiety signaling.
Provided strictly as scientific context.
3.) 28%
Reported increased energy levels in trials
Reported value in published research relating to GLP-1 multi-agonist compounds.
Provided strictly as a scientific reference point.
4.) 18.3 KG
Average weight loss during clinical trial period of 48 weeks on high-dose Retatrutide.
Example data point referenced in peer-reviewed studies for GLP-1 multi-agonists.
Alluvi does not promote or imply medical use of its products.